Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Adma Biologics (ADMA)

Adma Biologics (ADMA)
19.30 x 5 21.05 x 1
Post-market by (Cboe BZX)
19.70 -0.52 (-2.57%) 03/26/25 [NASDAQ]
19.30 x 5 21.05 x 1
Post-market 19.79 +0.09 (+0.46%) 18:58 ET
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
19.45
Day High
20.25
Open 20.18
Previous Close 20.22 20.22
Volume 2,182,300 2,182,300
Avg Vol 3,619,960 3,619,960
Stochastic %K 87.52% 87.52%
Weighted Alpha +112.33 +112.33
5-Day Change -0.91 (-4.42%) -0.91 (-4.42%)
52-Week Range 5.89 - 23.64 5.89 - 23.64
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,779,806
  • Shares Outstanding, K 236,390
  • Annual Sales, $ 426,450 K
  • Annual Income, $ 197,670 K
  • EBIT $ 139 M
  • EBITDA $ 148 M
  • 60-Month Beta 0.60
  • Price/Sales 11.26
  • Price/Cash Flow 37.51
  • Price/Book 13.76

Options Overview Details

View History
  • Implied Volatility 52.80% ( +1.30%)
  • Historical Volatility 54.85%
  • IV Percentile 20%
  • IV Rank 20.08%
  • IV High 171.68% on 04/05/24
  • IV Low 22.93% on 05/16/24
  • Put/Call Vol Ratio 0.91
  • Today's Volume 2,832
  • Volume Avg (30-Day) 4,928
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 50,786
  • Open Int (30-Day) 48,866

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.16
  • Number of Estimates 1
  • High Estimate 0.16
  • Low Estimate 0.16
  • Prior Year 0.08
  • Growth Rate Est. (year over year) +100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.50 +45.93%
on 03/04/25
Period Open: 15.78
20.70 -4.83%
on 03/25/25
+3.92 (+24.84%)
since 02/26/25
3-Month
13.50 +45.93%
on 03/04/25
Period Open: 17.89
20.70 -4.83%
on 03/25/25
+1.81 (+10.12%)
since 12/26/24
52-Week
5.89 +234.18%
on 04/10/24
Period Open: 6.50
23.64 -16.67%
on 11/11/24
+13.20 (+203.08%)
since 03/26/24

Most Recent Stories

More News
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook

CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.

IJR : 106.79 (-0.53%)
ADMA : 19.70 (-2.57%)
VTI : 281.16 (-1.17%)
XBI : 85.08 (-2.30%)
Adma Biologics: Q4 Earnings Snapshot

Adma Biologics: Q4 Earnings Snapshot

ADMA : 19.70 (-2.57%)
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

ADMA : 19.70 (-2.57%)
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

ADMA : 19.70 (-2.57%)
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

ADMA : 19.70 (-2.57%)
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?

We expect investors to focus on the sales performance of ADMA Biologics’ ADMA portfolio of marketed products and other pipeline updates when it reports fourth-quarter 2024 results.See the Zacks Earnings...

VKTX : 26.34 (-5.86%)
MIRM : 46.28 (-1.66%)
ADMA : 19.70 (-2.57%)
PCRX : 24.42 (-0.49%)
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

GRAL : 28.39 (-9.01%)
ADMA : 19.70 (-2.57%)
EXEL : 37.01 (-1.86%)
GLYC : 0.2441 (-5.24%)
MBRX : 1.0700 (-6.96%)
There May Still Be Time to Get in on These 3 Trending Biotechs

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

AVDL : 8.17 (-0.37%)
SANA : 1.81 (-15.81%)
IBB : 131.14 (-1.38%)
ADMA : 19.70 (-2.57%)
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

ADMA : 19.70 (-2.57%)
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025

ADMA : 19.70 (-2.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 20.95
2nd Resistance Point 20.60
1st Resistance Point 20.15
Last Price 19.70
1st Support Level 19.35
2nd Support Level 19.00
3rd Support Level 18.55

See More

52-Week High 23.64
Last Price 19.70
Fibonacci 61.8% 16.86
Fibonacci 50% 14.77
Fibonacci 38.2% 12.67
52-Week Low 5.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies